DMK
CHRS icon

David M. Knott’s Coherus Oncology CHRS Stock Holding History

David M. Knott’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.65M Buy
102,555
+2,900
+3% +$42.5K 0.6% 45
2021
Q2 		$1.38M Hold
99,655
– – 0.49% 48
2021
Q1 		$1.46M Sell
99,655
-2,000
-2% -$34K 0.62% 43
2020
Q4 		$1.77M Buy
101,655
+2,162
+2% +$38.5K 0.8% 33
2020
Q3 		$1.82M Sell
99,493
-5,073
-5% -$94.4K 1.07% 23
2020
Q2 		$1.87M Buy
104,566
+37,527
+56% +$635K 1.02% 26
2020
Q1 		$1.09M Sell
67,039
-8,675
-11% -$160K 0.69% 27
2019
Q4 		$1.36M Buy
75,714
+12,327
+19% +$227K 0.55% 33
2019
Q3 		$1.28M Buy
63,387
+1,000
+2% +$20K 0.54% 35
2019
Q2 		$1.38M Buy
62,387
+21,918
+54% +$381K 0.58% 31
2019
Q1 		$552K Buy
40,469
+100
+0.2% +$1.33K 0.22% 58
2018
Q4 		$365K Hold
40,369
– – 0.17% 60
2018
Q3 		$666K Buy
40,369
+49
+0.1% +$869 0.22% 54
2018
Q2 		$564K Hold
40,320
– – 0.21% 61
2018
Q1 		$446K Buy
40,320
+2,000
+5% +$21.9K 0.18% 63
2017
Q4 		$337K Buy
38,320
+4,000
+12% +$42.8K 0.13% 71
2017
Q3 		$458K Buy
34,320
+12,000
+54% +$159K 0.2% 62
2017
Q2 		$320K Buy
+22,320
New +$429K 0.13% 58

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

David M. Knott's CHRS Position: Q3 2021 in Review

David M. Knott increased its Coherus Oncology (CHRS) stake by 2.9% in Q3 2021, buying an estimated $42.5K and bringing the position to 102,555 shares worth $1.65M. The position accounts for 0.6% of the portfolio, ranked #45.

David M. Knott first reported a position in CHRS in Q2 2017 and has held it in 18 quarters since. The position peaked at $1.87M in Q2 2020. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • David M. Knott held 102,555 shares of Coherus Oncology worth $1.65M as of Q3 2021.
  • David M. Knott bought 2,900 Coherus Oncology shares in Q3 2021, an estimated $42.5K.
  • Coherus Oncology made up 0.6% of David M. Knott's portfolio in Q3 2021, its #45 holding.
  • David M. Knott first reported a position in Coherus Oncology in Q2 2017 and has held it in 18 quarters since.
  • David M. Knott's Coherus Oncology position peaked at $1.87M in Q2 2020.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.